Recent Updates
Recently added Catalysts
FBIO Positive Sentiment Score: 75/100

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

Key Takeaway: Fortress Biotech, Inc., an innovative biopharmaceutical company, announced the participation of its CEO, Lindsay A. Rosenwald, in the Alliance Global Partners Virtual Healthcare Company Showcase on May 21, 2024. This event highlights the company's focus on acquiring and advancing biopharmaceutical assets. Fortress has a comprehensive portfolio consisting of seven marketed prescription products and over 20 programs in development across various therapeutic areas including oncology and rare diseases. A replay of the discussion will be available on the company's website after the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Fortress Biotech is actively participating in a significant industry event.
  • The participation showcases Fortress’s innovative approach and thought leadership.
  • The company has a diverse portfolio with multiple developmental programs.

Full Press Release Details

MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 4:20 p.m. ET.
Please click here to register for the conference.
A replay of the fireside chat will be available shortly after the conference on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the meeting.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com.
Fortress Biotech, Inc.
Media Relations Contact:

Tags

Alliance Global Partners
Virtual Healthcare Showcase

Frequently Asked Questions

When will Fortress Biotech's fireside chat take place?

The fireside chat is scheduled for May 21, 2024, at 4:20 p.m. ET.

How can I access the replay of the fireside chat?

A replay will be available on Fortress' Events page for 30 days post-conference.

What is Fortress Biotech focused on?

Fortress Biotech focuses on acquiring and advancing biopharmaceutical assets.

How many products does Fortress Biotech have marketed?

Fortress has seven marketed prescription pharmaceutical products.

What therapeutic areas does Fortress Biotech target?

Fortress targets oncology, dermatology, and rare diseases for development.

Last updated: May 16, 2024